Production (Stage)
Ligand Pharmaceuticals Incorporated
LGND
$105.99
$1.811.74%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -149.28% | -270.93% | 30.19% | -2,366.86% | 105.34% |
| Total Depreciation and Amortization | -5.20% | -3.24% | -4.57% | -2.28% | -3.89% |
| Total Amortization of Deferred Charges | 25.80% | 27.01% | 111.68% | 16.73% | 3.69% |
| Total Other Non-Cash Items | 115.48% | 1,162.12% | -7.28% | 1,079.63% | -232.46% |
| Change in Net Operating Assets | -162.70% | 172.55% | 134.18% | -38.97% | 4.38% |
| Cash from Operations | -235.84% | 253.02% | 377.77% | 16,336.59% | -44.82% |
| Capital Expenditure | -103.81% | -70.74% | -22.38% | -100.99% | 95.65% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 239.18% | -284.22% | -433.17% | -800.49% | -128.31% |
| Cash from Investing | 229.64% | -275.56% | -138.46% | -824.71% | -135.79% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -40.00% | -20.00% | 28.57% | 99.99% | 61.54% |
| Issuance of Common Stock | -72.41% | 765.42% | 531.68% | 4.48% | 351.05% |
| Repurchase of Common Stock | -189.04% | -652.92% | -21.36% | 100.00% | 25.97% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -73.17% | -3,498.31% | -- | -- | -- |
| Cash from Financing | -138.97% | 283.59% | 1,584.40% | 114.01% | 1,671.87% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -189.61% | 180.62% | 629.64% | 46.99% | -37.93% |